Dutasteride and prostate cancer [4]

New England Journal of Medicine

Volumn 363, Issue 8, 2010, Pages 794-

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; AZASTEROID; ENZYME INHIBITOR; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

CANCER GRADING; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CLINICAL PRACTICE; HIGH RISK POPULATION; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; RISK REDUCTION; BIOPSY; BLOOD; DRUG ANTAGONISM; NOTE; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

AZASTEROIDS; BIOPSY; ENZYME INHIBITORS; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 77955871814     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:S14-S19. (Pubitemid 47224952)
2. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007;100:540-3.
3. Fang F, Keating NL, Mucci LA, et al. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst 2010;102:307-14.
4. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila Pa) 2008;1:174-81.